Home
Login Register
Biosensors   

Is Biosensors a good buy?

 Post Reply 3361-3380 of 10899
 
allright
    01-Feb-2011 08:38  
Contact    Quote!


LOOKS like the 2 other vendors backed out of the agreement to sell their shares. Probably because the price ran up?

On 30 January 2011, Autumn Eagle entered into termination agreement to terminate the SPAs with the two remaining vendors in respect of 50,000,000 issued ordinary shares in the capital of Biosensors (the " Relevant Shares" ). 
 


 
NOTICE OF A CHANGE IN THE PERCENTAGE LEVEL OF A SUBSTANTIAL SHAREHOLDER'S INTEREST *
* Asterisks denote mandatory information
 
" DISCLAIMER:- This announcement was prepared and issued by the below mentioned listed issuer to the Exchange. The Exchange assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained in this announcement and is posting this announcement on SGXNET for the sole purpose of dissemination only. In the event of any queries or clarification required in respect of any matters arising from this announcement, such queries are to be made to the listed issuer directly and not to the Exchange. The Exchange shall not be liable for any losses or damages howsoever arising as a result of the circulation, publication and dissemination of this announcement."
 
Name of Announcer * BIOSENSORS INT'L GROUP, LTD.  
Company Registration No. EC 24983  
Announcement submitted on behalf of BIOSENSORS INT'L GROUP, LTD.  
Announcement is submitted with respect to * BIOSENSORS INT'L GROUP, LTD.  
Announcement is submitted by * Yoh-Chie Lu  
Designation * Chairman  
Date & Time of Broadcast 01-Feb-2011 07:22:06  
Announcement No. 00012  
 
 
> > ANNOUNCEMENT DETAILS
The details of the announcement start here ...
 
> > PART I
 
1. Date of notice to issuer * 31-01-2011  
 
2. Name of Substantial Shareholder * Hony Capital Fund 2008 GP Limited (" HCF 2008 GP Limited" ) 
 
3. Please tick one or more appropriate box(es): *
 
  • Notice of a Change in the Percentage Level of a Substantial Shareholder's Interest or Cessation of Interest. [Please complete Part III and IV]
  •  
     
    > > PART II
     
    1. Date of change of [Select Option]  
     
    2. Name of Registered Holder  
     
    3. Circumstance(s) giving rise to the interest or change in interest [Select Option]  
      # Please specify details
       
     
    4. Information relating to shares held in the name of the Registered Holder
     
    No. of [Select Option] held before the change  
    As a percentage of issued share capital %
     
    No. of N.A. which are subject of this notice  
    As a percentage of issued share capital %
     
    Amount of consideration (excluding brokerage and stamp duties) per share paid or received  
     
    No. of N.A. held after the change  
    As a percentage of issued share capital %
     
     
    > > PART III
     
    1. Date of change of Deemed Interest 30-01-2011  
     
    2. The change in the percentage level From 28.89 % To 24.37 %
     
    3. Circumstance(s) giving rise to the interest or change in interest # Others  
      # Please specify details
    On 10 October 2010, Autumn Eagle entered into sale and purchase agreements (the " SPAs" ) with seven vendors whereby the vendors agreed to sell and Autumn Eagle agreed to purchase, on the terms and conditions set out in the SPAs, an aggregate of 319,312,200 issued ordinary shares in the capital of Biosensors.

    On 3 November 2010, Autumn Eagle completed the acquisition of an aggregate of 269,312,200 issued ordinary shares in the capital of Biosensors from five of the vendors.

    On 30 January 2011, Autumn Eagle entered into termination agreement to terminate the SPAs with the two remaining vendors in respect of 50,000,000 issued ordinary shares in the capital of Biosensors (the " Relevant Shares" ).

    HCF 2008 GP Limited is the general partner of Hony Capital Fund 2008 GP L.P., which in turn is the general partner of Hony Capital Fund 2008 L.P.. Hony Capital Fund 2008 L.P. owns 100 per cent of Autumn Eagle. Accordingly, HCF 2008 GP Limited no longer has a deemed interest in the Relevant Shares.  
     
    4. A statement of whether the change in the percentage level is the result of a transaction or a series of transactions:
    The change in the percentage level is the result of a series of transactions.  
     
     
    > > PART IV
     
    1. Holdings of Substantial Shareholder , including direct and deemed interest :
     
    Direct
    Deemed
    No. of shares held before the change 0   319,312,200  
    As a percentage of issued share capital 0 % 28.89 %
    No. of shares held after the change 0   269,312,200  
    As a percentage of issued share capital 0 % 24.37 %
     
    Footnotes
    In this notification, the percentage of shareholding is expressed based no 1,105,296,021 ordinary shares as at 28 January 2011.  
     
    displayAttachments_LN::

    displayAttachmentsLength_LN::
    Attachments
    Total size = 0
    (2048K size limit recommended)




     
     
    allright
        01-Feb-2011 08:15  
    Contact    Quote!
    DBS Vickers   advise HOLD- TP $1.20. OCBC is BUY -TP up $1.36 from $1.35.
     
     
    abkxpres
        01-Feb-2011 05:32  
    Contact    Quote!
    OCBC dumping biosensors yesterday seen in the queue.   How come they advised hold and TP at $1.20 but behind everybody's back is off loading......:(

    allright      ( Date: 31-Jan-2011 11:03) Posted:

    DBS Vickers
    Biosensors International Group, HOLD S$1.14, Bloomberg: BIG SP
    No surprises
    Price Target : S$ 1.20
    By: Singapore Research Team +65 6533 9688

    ·      3Q FY11 result in line, on track to meet our full year forecast

    ·      Gaining share in all markets

    ·      No update on China and Japan approvals

    ·      Estimates intact, maintain Hold and S$1.20 TP


    Comment on Result
    Revenue grew 32% yoy to US$42.5m, while earnings grew 8% to US$13.3m.
    Revenue growth was driven by market share gains for DES stents. BIG had
    mentioned earlier that it had a 15% market share outside of the US
    ex-Japan we now have a reason to believe its market share is between 15%
    and 20%. 3Q FY11 was also operationally more profitable as EBIT margin
    improved from 24% to 31% due to successful cost containment. Meanwhile,
    BIG’s cash balance rose to US$81.7m from US$71.3m last quarter, as the
    business generated US$8.2m operating cashflow.

    There was no further update on China and Japan product approvals. But
    looking at its launch pipeline, management is targeting to launch Devax
    stent at next year’s Euro PCR and to secure CE mark for BioFreedom in FY12.
    We believe Abbott’s ABSORB bioresorable stent, planned for 2H 2012 launch,
    could provide stiff competition to BIG’s current technology. Hence, BIG
    would need to commercialise BioFreedom as well as launch BioMatrix in Japan
    and China, before Abbott’s bioresorable technology catches up.

    Recommendation
    We are retaining FY11F/FY12F earnings of US$37m/US$50m. Our price target
    for BIG is unchanged at S$1.20. We have priced in market share gains in our
    projections, and believe further upside will be triggered by Japan and
    China approvals. Maintain Hold.

    (Document link: Singapore Research)

     

     
    allright
        31-Jan-2011 11:03  
    Contact    Quote!
    DBS Vickers
    Biosensors International Group, HOLD S$1.14, Bloomberg: BIG SP
    No surprises
    Price Target : S$ 1.20
    By: Singapore Research Team +65 6533 9688

    ·      3Q FY11 result in line, on track to meet our full year forecast

    ·      Gaining share in all markets

    ·      No update on China and Japan approvals

    ·      Estimates intact, maintain Hold and S$1.20 TP


    Comment on Result
    Revenue grew 32% yoy to US$42.5m, while earnings grew 8% to US$13.3m.
    Revenue growth was driven by market share gains for DES stents. BIG had
    mentioned earlier that it had a 15% market share outside of the US
    ex-Japan we now have a reason to believe its market share is between 15%
    and 20%. 3Q FY11 was also operationally more profitable as EBIT margin
    improved from 24% to 31% due to successful cost containment. Meanwhile,
    BIG’s cash balance rose to US$81.7m from US$71.3m last quarter, as the
    business generated US$8.2m operating cashflow.

    There was no further update on China and Japan product approvals. But
    looking at its launch pipeline, management is targeting to launch Devax
    stent at next year’s Euro PCR and to secure CE mark for BioFreedom in FY12.
    We believe Abbott’s ABSORB bioresorable stent, planned for 2H 2012 launch,
    could provide stiff competition to BIG’s current technology. Hence, BIG
    would need to commercialise BioFreedom as well as launch BioMatrix in Japan
    and China, before Abbott’s bioresorable technology catches up.

    Recommendation
    We are retaining FY11F/FY12F earnings of US$37m/US$50m. Our price target
    for BIG is unchanged at S$1.20. We have priced in market share gains in our
    projections, and believe further upside will be triggered by Japan and
    China approvals. Maintain Hold.

    (Document link: Singapore Research)
     
     
    metaphoricsymbol
        31-Jan-2011 09:51  
    Contact    Quote!


    Today Biosensors  price  may be kept low by the MBL ecw 110201 warrant expiring tomorrow. Also today follow the broadmarket  knee jerk reaction over the worsening of situation at Egypt over the weekend - but could recover some lost ground tomorrow. So I believe  Biosensors price will only move up significantly tomorrow.
     
     
    allright
        31-Jan-2011 09:23  
    Contact    Quote!


    Hope its different this time. this is from OCBC Research
    Biosensors International Group: Growth driven by increasing market share

    Summary:  Biosensors International Group (BIG) reported its 3Q11 results with revenue increasing 31.8% YoY and 16.8% QoQ to US$42.6m. Net profit increased 7.8% YoY and 57.6% QoQ to US$13.3m. Excluding exceptional items, net profit would have increased 20.3% YoY and 33.4% QoQ to US$14.9m. Revenue was within our expectation of US$43.6m although core earnings were slightly higher than our forecast of US$13.9m. For 9M11, revenue increased 34.5% to US$112.1m, meeting 70.9% of our FY11 forecast while core net profit rose 55.2% to US$36.0m, forming 72.9% of our full-year earnings figure. Management expects profitability for 2H11 to be higher than that of 1H11. As expected, growth was once again driven by BIG’s BioMatrix family of drug-eluting stents (DES), with across-the-board organic growth in all geographical locations. Moving forward, BIG is seeking to expand its product portfolio, via new product launches and strategic acquisitions that complements its portfolio. We remain sanguine about BIG’s growth prospects and incorporate the latest figures in our assumptions. As such, our DCF-based fair value estimate increases marginally from S$1.35 to S$1.36. Reiterate  BUY 

    gbleng      ( Date: 31-Jan-2011 09:10) Posted:

    So typical of BIG, good news amidst market turmoil.... seen it time and time again...

     

     
    gbleng
        31-Jan-2011 09:10  
    Contact    Quote!
    So typical of BIG, good news amidst market turmoil.... seen it time and time again...
     
     
    dmgsecs
        31-Jan-2011 03:06  
    Contact    Quote!


    just a side note vickers posted on P ong's privatisation, JAP PATENTS, and how much the mkt is worth if it comes true this week... upgrades from various houses will come after.



    sept issue of the edge-


    DBS Vickers says heart-stent maker technologically ahead of rivals, well positioned to gain market share: “Biosensors is awaiting approvals for its product to be sold in Japan and China. There could be room for earnings upgrades once these are granted.”


    Broker notes stent market in both countries worth combined U$800 million-U$1 billion ($1.1 billion-$1.3 billion). Thinks company an attractive takeover target for larger peers, while upcoming HK listing of MicroPort Scientific, which makes equipment for keyhole surgery, could help boost interest in Biosensors.




    PeterOng_21      ( Date: 29-Jan-2011 18:52) Posted:



    With japanese stent patent approval (do ur research.. the majority of japans stent patents approval are within the 1st week of feb with outliers in Oct) BIG's CEO in last wks earnings conference states jap's patent approval well underway and due 1H2011!!... connect the dots!!.


    Record net earnings upon another record earnings qoq (supposed to be 14.8m USD BUT FOR the depreciation in warrants that made it 13.3m USD) should have been double the mutiple at 15% qoq, extremely bullish indicator for earnings results.

    Ongoing privatisation theme  as well by chinese corps wanting to buy over US medical equipment co. (which better than one that's already 30% owned by chinese (govt linked) private equity fund to tap their own chinese market.. so smart... juzt to provide a few catalysts for the stock.. not needed perhaps...

    as neither is its technical oscillators showing RSI and Stochastics bullish convergence at last trading 1.14 prior to earnings report 28th evening ;D . I guess confirmation of reversal that has been already done when it broke 1.15 (20/50 day moving avg resistance- 20th) trading up to 1.18/1.19 on the 20th isn't a SIGN of bullishness... perhaps the consolidation phase has ended as well with support at 1.12, hardly any downside risk from 1.14... provided key resistance is at 1.25/1.26... connect the dots... i need not say much... positive catalysts have finally come within the upcoming trading week.. positive technicals.. positive earnings.. should see it trade at or above fair value of $1.22 justified by its 3Q2011 x P/E ... now that's a ??... EIGHT PERCENT DISCOUNT to last close at 1.14... good buy or not... you tell me... exponential upside... limited downside cos near support... really.... who needs to worry about technicals when fundamentally a stock like this is so strong with earnings up side exponential if it gets taken over... the only reason why it was depressed last week btw 1.13-1.15... is because 1)consolidation before earnings by traders and 2) warrants expiring 1 feb - 95 cents.. now with certainty of exceptional earnings and without barriers in the way ... its about time it trades above 1.20 levels.. not forgetting the conference speech by CEO, saying that financial guidance for FY2011  is positive and very confident of FY2011 earnings come 31st march, which should dampen bio's investors anxiety about performance.      

    Guys, the upcoming trading week is short due to cny.. with 2 full trading days... all i can say is... EARLY BIRD CATCHES THE WORM...come monday break for 1.18/1.19 then up to 1.20 levels to trade on earnings result. Further momentum if patents approved come next week.. 




     
     
    dmgsecs
        31-Jan-2011 02:26  
    Contact    Quote!


    monday- traders for 1.19 first in morning session then 1.20's in afternoon

    BIG most likely the only counter to be moving out of earnings on back of positive results as other stocks all negative.. will see liquidity flood here as big boys push out of consolidation on price action northwards. 

    like P ong says below fair value much higher than 1.14.. counter just lack catalyst and also cos of accumulation for this push. going forward bui dai ji liao.  


    WILL test 1.25/1.26 levels before key resistance turns support.. prop desks coming in tmr on vol. and techinicals.


     
     
     
    abkxpres
        29-Jan-2011 19:50  
    Contact    Quote!
    Wah!...You all say until this counter must sure fly.  Cannot wait I will queue for this counter at least 300 lots and buy no matter what price.  PUT MONEY TAKE MONEY for the CNY.  Huat Ah!!!

    PeterOng_21      ( Date: 29-Jan-2011 18:52) Posted:



    With japanese stent patent approval (do ur research.. the majority of japans stent patents approval are within the 1st week of feb with outliers in Oct) BIG's CEO in last wks earnings conference states jap's patent approval well underway and due 1H2011!!... connect the dots!!.


    Record net earnings upon another record earnings qoq (supposed to be 14.8m USD BUT FOR the depreciation in warrants that made it 13.3m USD) should have been double the mutiple at 15% qoq, extremely bullish indicator for earnings results.

    Ongoing privatisation theme  as well by chinese corps wanting to buy over US medical equipment co. (which better than one that's already 30% owned by chinese (govt linked) private equity fund to tap their own chinese market.. so smart... juzt to provide a few catalysts for the stock.. not needed perhaps...

    as neither is its technical oscillators showing RSI and Stochastics bullish convergence at last trading 1.14 prior to earnings report 28th evening ;D . I guess confirmation of reversal that has been already done when it broke 1.15 (20/50 day moving avg resistance- 20th) trading up to 1.18/1.19 on the 20th isn't a SIGN of bullishness... perhaps the consolidation phase has ended as well with support at 1.12, hardly any downside risk from 1.14... provided key resistance is at 1.25/1.26... connect the dots... i need not say much... positive catalysts have finally come within the upcoming trading week.. positive technicals.. positive earnings.. should see it trade at or above fair value of $1.22 justified by its 3Q2011 x P/E ... now that's a ??... EIGHT PERCENT DISCOUNT to last close at 1.14... good buy or not... you tell me... exponential upside... limited downside cos near support... really.... who needs to worry about technicals when fundamentally a stock like this is so strong with earnings up side exponential if it gets taken over... the only reason why it was depressed last week btw 1.13-1.15... is because 1)consolidation before earnings by traders and 2) warrants expiring 1 feb - 95 cents.. now with certainty of exceptional earnings and without barriers in the way ... its about time it trades above 1.20 levels.. not forgetting the conference speech by CEO, saying that financial guidance for FY2011  is positive and very confident of FY2011 earnings come 31st march, which should dampen bio's investors anxiety about performance.      

    Guys, the upcoming trading week is short due to cny.. with 2 full trading days... all i can say is... EARLY BIRD CATCHES THE WORM...come monday break for 1.18/1.19 then up to 1.20 levels to trade on earnings result. Further momentum if patents approved come next week.. 




     

     
    PeterOng_21
        29-Jan-2011 18:52  
    Contact    Quote!


    With japanese stent patent approval (do ur research.. the majority of japans stent patents approval are within the 1st week of feb with outliers in Oct) BIG's CEO in last wks earnings conference states jap's patent approval well underway and due 1H2011!!... connect the dots!!.


    Record net earnings upon another record earnings qoq (supposed to be 14.8m USD BUT FOR the depreciation in warrants that made it 13.3m USD) should have been double the mutiple at 15% qoq, extremely bullish indicator for earnings results.

    Ongoing privatisation theme  as well by chinese corps wanting to buy over US medical equipment co. (which better than one that's already 30% owned by chinese (govt linked) private equity fund to tap their own chinese market.. so smart... juzt to provide a few catalysts for the stock.. not needed perhaps...

    as neither is its technical oscillators showing RSI and Stochastics bullish convergence at last trading 1.14 prior to earnings report 28th evening ;D . I guess confirmation of reversal that has been already done when it broke 1.15 (20/50 day moving avg resistance- 20th) trading up to 1.18/1.19 on the 20th isn't a SIGN of bullishness... perhaps the consolidation phase has ended as well with support at 1.12, hardly any downside risk from 1.14... provided key resistance is at 1.25/1.26... connect the dots... i need not say much... positive catalysts have finally come within the upcoming trading week.. positive technicals.. positive earnings.. should see it trade at or above fair value of $1.22 justified by its 3Q2011 x P/E ... now that's a ??... EIGHT PERCENT DISCOUNT to last close at 1.14... good buy or not... you tell me... exponential upside... limited downside cos near support... really.... who needs to worry about technicals when fundamentally a stock like this is so strong with earnings up side exponential if it gets taken over... the only reason why it was depressed last week btw 1.13-1.15... is because 1)consolidation before earnings by traders and 2) warrants expiring 1 feb - 95 cents.. now with certainty of exceptional earnings and without barriers in the way ... its about time it trades above 1.20 levels.. not forgetting the conference speech by CEO, saying that financial guidance for FY2011  is positive and very confident of FY2011 earnings come 31st march, which should dampen bio's investors anxiety about performance.      

    Guys, the upcoming trading week is short due to cny.. with 2 full trading days... all i can say is... EARLY BIRD CATCHES THE WORM...come monday break for 1.18/1.19 then up to 1.20 levels to trade on earnings result. Further momentum if patents approved come next week.. 



     
     
    PeterOng_21
        29-Jan-2011 16:35  
    Contact    Quote!
    m,n
     
     
    lowchia
        29-Jan-2011 01:36  
    Contact    Quote!


    On Friday, Biosensors continue to trend sideway and closed at $1.14 with LOW volume of 3.26 million shares traded.

    A long lower shadow occurred.  This is typically a bullish signal (particularly when it occurs near a low price level, at a support level, or when the security is oversold).

    RSI & MACD are flat as MACD lines are converge together.

    Important Resistance of Biosensors: $1.18

    Immediate Support of Biosensors: $1.11

    Currently prices are resisted by the 50/200 days MA and supported by 100 days MA at $1.11

    From the chart, we could see that Biosensors is currently forming....................READ MORE
     
     
    james87
        28-Jan-2011 22:48  
    Contact    Quote!
    Hopefully it will have some effect on the share price...Biosensor always choose the wrong time to announce good news. Often, the share plummet down due to regional sentiment...

    bsiong      ( Date: 28-Jan-2011 22:27) Posted:



    Biosensors posts 7.3% rise in 3Q net profit to $17m

     
    WRITTEN BY THE EDGE   


    FRIDAY, 28 JANUARY 2011 19:49

    Biosensors International Group, today reported a net profit of US$13.3 million ($17 million) for its third fiscal quarter (3Q FY11), compared to US$12.4 million in 3Q FY10.

    Total product sales in the third quarter were US$37.9 million, a 17% increase over the previous quarter (2Q FY11), and a 27% increase over the US$29.8 million reported in 3Q FY10. Overall growth was driven largely by continued growth in the sales of the BioMatrix family of drug‐eluting stents (DES), which increased to US$26.3 million, up 26% over 2Q FY11 and 60% over 3Q FY10.

    Sales of other interventional cardiology products in Q3 FY11 were US$7.9 million, a 20% decrease over Q3 FY10 due to reduced OEM sales in Asia. Sales of critical care products increased 7% to US$3.6 million from US$3.4 million in Q3 FY10. Total revenue for Q3 FY11, including licensing revenue and royalties, was US$42.6 million, up 32% over the US$32.3 million reported in Q3 FY10.

    Jack Wang, Co-CEO and acting CFO, says, “Biosensors has done well to enter into its thirteenth consecutive quarter of product sales growth. The increase in DES sales was driven by increased sales of the BioMatrix DES family in existing markets, continued expansion into new markets through regulatory approvals, and the successful launch of our BioMatrix Flex product. The increase in licensing revenue and royalties was due to increased DES sales of a licensee. We remain on track to achieve our revenue and profitability targets for fiscal 2011.”



    Based on its performance through December 2010 and consistent with previous financial guidance, Biosensors expects product revenues for the fiscal year ending 31 March 2011 (FY11) to range between US$135 million and US$145 million.

     

     

    /edge/

     


     
     
    bsiong
        28-Jan-2011 22:27  
    Contact    Quote!


    Biosensors posts 7.3% rise in 3Q net profit to $17m

     
    WRITTEN BY THE EDGE   


    FRIDAY, 28 JANUARY 2011 19:49

    Biosensors International Group, today reported a net profit of US$13.3 million ($17 million) for its third fiscal quarter (3Q FY11), compared to US$12.4 million in 3Q FY10.

    Total product sales in the third quarter were US$37.9 million, a 17% increase over the previous quarter (2Q FY11), and a 27% increase over the US$29.8 million reported in 3Q FY10. Overall growth was driven largely by continued growth in the sales of the BioMatrix family of drug‐eluting stents (DES), which increased to US$26.3 million, up 26% over 2Q FY11 and 60% over 3Q FY10.

    Sales of other interventional cardiology products in Q3 FY11 were US$7.9 million, a 20% decrease over Q3 FY10 due to reduced OEM sales in Asia. Sales of critical care products increased 7% to US$3.6 million from US$3.4 million in Q3 FY10. Total revenue for Q3 FY11, including licensing revenue and royalties, was US$42.6 million, up 32% over the US$32.3 million reported in Q3 FY10.

    Jack Wang, Co-CEO and acting CFO, says, “Biosensors has done well to enter into its thirteenth consecutive quarter of product sales growth. The increase in DES sales was driven by increased sales of the BioMatrix DES family in existing markets, continued expansion into new markets through regulatory approvals, and the successful launch of our BioMatrix Flex product. The increase in licensing revenue and royalties was due to increased DES sales of a licensee. We remain on track to achieve our revenue and profitability targets for fiscal 2011.”



    Based on its performance through December 2010 and consistent with previous financial guidance, Biosensors expects product revenues for the fiscal year ending 31 March 2011 (FY11) to range between US$135 million and US$145 million.

     

     

    /edge/

     

     

     
    investor
        28-Jan-2011 21:57  
    Contact    Quote!


    Having gone thru the audio conference, the points that I thought were important are as follows :

    1.) Strong DES sales of US$26.3m compared to previous Qtr of US$20.9m, a 26 % growth qtr-on-qtr. (Looks like Jeff Jump was not kidding in his previous comments in last conference)

    2.) In reply to a question on which country is gaining more mkt share - Jeff says that the Biomatrix is gaining mkt share across the board, quite uniformly, and the impression given by him, is that it will continue to gain mkt share going forward.

    3.) Biosensors HAS ALREADY submitted the Biofreedom for CE mark approval, and are expecting it to be approved in FY 2012 (ie between Apr 2011 to Mar 2012).

    By the way, that was what I thought the last time too (ie submission for approval), but a few people in this forum thought otherwise.

    4). The Devax product will be launched sometime in May this year (during EuroPCR).

    5.) When asked about the timeline for approval for Japan - although he was uncertain, he did mentioned that most people (analysts) assume that it should be within the first half of this yr.

    6.) Net profit was US$13.3m for this qtr, and without taking into consideration the non-cash item of US$1.5m for warrant depn, the net profit would have been US$14.8m!

    All in all, the results exceeded my personal expectation.

    Again, not a call to buy/sell. Investors are advised to do their own analysis.
     
     
    allright
        28-Jan-2011 18:18  
    Contact    Quote!
    NEWS RELEASE
    Biosensors Announces Continued Growth in Sales and Profitability for Third 
    Quarter and Nine Months of Fiscal Year Ending 31 March 2011
    Singapore, 28 January 2011 ‐ Biosensors International Group, Ltd. (“Biosensors” or  the 
    “Group”, Bloomberg: BIG SP) today announced  financial results for its third fiscal quarter 
    (“Q3 FY11”) and nine months ended 31 December 2010 (“FY11 nine‐month period”).
    Total product sales in the third quarter were US$37.9 million, a  17% increase over the 
    previous quarter (“Q2 FY11”), and a 27% increase over the US$29.8 million reported in the 
    third quarter of fiscal year 2010 (“Q3 FY10”). Overall growth was driven largely by continued 
    growth in the sales of the BioMatrix™ family of drug‐eluting stents (“DES”), which increased 
    to  US$26.3  million,  up  26%  over  Q2 FY11 and  60% over Q3 FY10. Sales of other 
    interventional cardiology products in Q3 FY11 were US$7.9 million, a 20% decrease over Q3
    FY10 due to  reduced OEM sales in Asia.  Sales  of critical care products increased 7%  to 
    US$3.6  million from US$3.4 million in Q3 FY10. Total revenue for Q3 FY11, including 
    licensing revenue and royalties, was US$42.6 million, up 32% over the US$32.3 million 
    reported in Q3 FY10.
    Product revenues for the FY11 nine‐month period rose by 29% compared to  those for the 
    FY10 nine‐month period. As with  product revenue growth for Q3 FY11, the increase was 
    driven by DES sales growth. Combined with increased licensing revenue, total revenue for 
    the first nine months of FY11 was US$112.1 million, compared to US$83.4 million for same 
    period in FY10, a 34% increase.
    Dr. Jack Wang, Co-CEO and  acting  CFO said, “Biosensors has done well to enter into its 
    thirteenth consecutive quarter of product sales growth. The increase in DES sales was driven 
    by increased sales of the BioMatrix DES family in existing markets, continued expansion into 
    new markets through regulatory approvals, and the successful  launch of our BioMatrix Flex
    product. The increase in licensing revenue and royalties was due to increased DES sales of a 
    licensee. We remain on track to achieve our revenue and profitability targets for fiscal 
    2011.”
    Sales and marketing expenses were US$11.0 million in Q3 FY11 compared to US$7.5 million 
    in Q3 FY10, and US$31.8 million for the FY11 nine‐month period compared to US$22.8 
    million for the FY10 nine-month period. The increase was mainly due to higher headcount 
    costs as  the Group  continued  to expand  its  sales force and global marketing activities, as 
    well as to increased warehousing and sales expenses.
     
     
    metaphoricsymbol
        27-Jan-2011 15:12  
    Contact    Quote!


    This being the first quarter under new management, it is important to inspire confidence. As such I do not expect negative surprises. Though I believe profitability of DES is under downward pressure because of price compettion, I believe their continued "increase in market share" will help alleviate this squeeze on margin and so Biosensors can still see significant jump in earnings in coming quarter's report.
     
     
    ragingbull
        27-Jan-2011 09:50  
    Contact    Quote!

    Highlighted today in the Wall Street Journal.  At the recent DAVOS conference in Switzerland, Legend Holdings Ltd.,  Chairman Liu Chuanzhi, quoted "Legend was looking at a US medical equipment company."  It seems clear that Legend is eager to enter the lucrative US market and it would seem this investment would be a catalyst for Biosensors and it's DES program.  The US DES market is considered to be about 50% of the WW market.  This is an observation, not a recommendation to buy or sell

    Chinese Firms Set Sights on U.S. Investments

    White House Welcomes Possible Infrastructure Stakes by Giant Sovereign-Wealth Fund, but Recommends Treading Gingerly



    DAVOS, Switzerland—Key Chinese companies are considering stepped-up investment in the U.S., particularly in infrastructure, and the White House is encouraging them to move ahead.

    In an interview with WSJ's Rebecca Blumenstein, Liu Chuanzhi, chairman of Lenovo Group, the world's fourth-largest computer company by sales, says he expects to see more Chinese investment in the United States.



    The prospects for fresh Chinese investment were discussed at a meeting last week between Chinese business leaders and the American and Chinese presidents during a state visit to Washington.

    One of the participants, Liu Chuanzhi, chairman of Chinese computer company Lenovo Group Ltd., said in an interview Wednesday at the World Economic Forum at Davos that he was among those seeking to deepen his U.S. investment.

    At the meeting, President Barack Obama and the head of China's Investment Corp., the country's $300 billion sovereign-wealth fund, talked about the Chinese investing in infrastructure projects in the U.S.

    "The United States is open for investment and would welcome it," Mr. Obama told the group, which included four Chinese CEOs, 14 American CEOs and Chinese President Hu Jintao.

    Mr. Liu on Wednesday said Lou Jiwei, the chairman of CIC, had told Mr. Obama that he "was interested in exploring the opportunity."

    "If it's complementary and good for both sides, why not?" said Mr. Liu, one of China's most respected business leaders.

    The talk of U.S. investments comes as waves of capital are going in the opposite direction—from developed countries like the U.S. into emerging economies like China—as companies chase higher growth rates. But Mr. Liu said Chinese companies continue to see opportunities to invest in the U.S., because it addresses Chinese companies' need to expand abroad while furthering the U.S. goal of keeping jobs.

    "These Chinese companies, when they go abroad, do so out of business necessity," said Mr. Liu, who co-founded Lenovo, the world's fourth-largest computer company by sales, and is also chairman of its parent, Legend Holdings Ltd. "I call this the evolution of Chinese business."

    From the U.S. perspective, foreign investment generally translates into jobs. White House officials see potential for foreign companies to build manufacturing plants in the U.S., despite higher U.S. labor costs, to bring goods closer to consumers in the world's largest economy.

    "For China to invest in the U.S., in much the same way the Japanese did in the '90s and beyond, to create jobs and manufacture products here, could be quite a constructive contribution to our growth and to better relations between our two countries," a senior White House official said. "We see foreign investment as a key part of our effort to create jobs and growth."

    The interest in infrastructure, which the Chinese have brought up in earlier meetings, also fits into the White House push for more investment in roads, airports and other projects, a point Mr. Obama highlighted in Tuesday's State of the Union address.
    RFR_LENOVO
    European Pressphoto Agency

    Lenovo's Liu Chuanzhi speaks at the Asia Financial Forum in Hong Kong Jan. 17.



    The Obama administration is aware of the dicey politics that could surround Chinese ownership of key infrastructure projects, such as an airport or a toll road. U.S. officials have encouraged the Chinese to be thoughtful about how they approach this and consider taking minority, passive stakes in larger projects.

    During their visit last week, Messrs. Obama and Hu both spoke warmly of Chinese investment in the U.S. at the start of the meeting with the business executives.

    "We've got some Chinese business leaders here, who I know are already doing business in the United States, making investments in the United States, engaging in joint ventures in the United States, and helping grow the economy here in the United States," Mr. Obama said. "I know they're interested in finding ways that they can expand their activities in the United States."

    Mr. Hu voiced a similar sentiment. "I also have a message to Chinese entrepreneurs. That is, the Chinese government will, as it has always done, support you in making investments and doing business here in the United States," he said.

    A CIC spokeswoman declined to comment on Mr. Liu's remarks last week with Mr. Obama. But CIC has made infrastructure investments before. In March, it finalized a deal to pay $1.58 billion for a 15% stake in AES Corp., a major U.S. power generation and distribution company.

    Last fall, a CIC official said the fund would be interested in financing U.S. infrastructure projects as a passive investor, not as a majority owner.

    "We are advocating that the U.S. government start a program to invest a massive amount of equity, in the form of public and private-equity partnership, in U.S. infrastructure," Zhou Yuan, head of asset allocation at CIC, said at a conference in New York in October.

    He said infrastructure projects, such as high-voltage transmission lines, will help create more jobs in the U.S. than the Federal Reserve's quantitative-easing policy.

    Lenovo is one of the most active Chinese investors in the U.S., with some 2,000 employees in the country, according to the company. It set a milestone for Chinese investment in the U.S. with its 2005 purchase of International Business Machines Corp.'s PC business.

    And Mr. Liu said Legend was looking at a U.S. medical-equipment company and purchases in the hospitality sector, to accommodate waves of Chinese tourists.

    Legend Holdings is an investment conglomerate partly owned by the Chinese government. It has property, private-equity and other holdings in addition to its controlling stake in Lenovo, of which it owns more than 40%.

    In the PC business, Mr. Liu said he was optimistic about Lenovo's prospects of lifting market share in emerging markets and the U.S.

    In the U.S., Lenovo is the fastest-growing vendor, with a market share of 5.6% in the third quarter, according toresearch firm International Data Corp.
     
     
    topdog22
        27-Jan-2011 08:00  
    Contact    Quote!
    It will be interesting to see how the new Investor Relations person handles this earnings release.  In the past, it was "small time".  Any thoughts?
     
    Important: Please read our Terms and Conditions and Privacy Policy .